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Management Update
Abhinav Dhami and Ravinder Kaur Malhi
Abstract
Cytomegalovirus, herpes simplex, and herpes zoster are responsible for the 
majority of cases of viral retinitis and can occur in both healthy and immunocom-
promised or immunodeficient individuals. Herpes zoster has been strongly incrimi-
nated as a causal agent in acute retinal necrosis in immunocompetent patients. 
Epstein Barr virus has been described in various ocular inflammatory diseases 
including multifocal choroiditis in healthy patients. In immunocompromised or 
immunodeficient patients, various opportunistic viral infections can occur; the 
most common being cytomegalovirus (CMV) infection. Other less common viruses 
causing retinal infections include herpes simplex virus (HSV) and varicella zoster 
virus (VZV). The vision-threatening complications associated with infectious viral 
disease are disastrous in nature due to rapid progression. The inability to control 
this viral retinitis requires early detection by the clinician with prompt and aggres-
sive initiation of the drug therapy to prevent complications.
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1. Introduction
Viral retinitis is an important vision threatening infectious disease of the retina 
which can occur in both immunocompetent and immunocompromised or immu-
nodeficient acquired immunodeficiency syndrome (AIDS) individuals. In immu-
nocompetent patients, acute retinal necrosis (ARN) has been recognized as a vision 
threatening inflammation caused primarily by herpes group of viruses while Epstein 
Barr virus (EBV) is associated with various ocular inflammatory diseases including 
multifocal choroiditis in healthy patients [1]. The immunocompromised or immuno-
deficient patients are predisposed to a higher risk for viral infections with the most 
common being cytomegalovirus (CMV) infection and the less commonly affecting 
viruses include herpes simplex virus (HSV) and varicella zoster virus (VZV) [1].
2. Acute retinal necrosis
It is characterized by the initial onset of episcleritis or scleritis, periorbital pain, 
and anterior uveitis, which may be granulomatous or stellate in appearance and lead to 
decreased vision resulting from vitreous opacification (Figure 1a), necrotizing retinitis, 
and, in some cases, optic neuritis or neuropathy. The American Uveitis Society released 
its criteria for diagnosis of acute retinal necrosis syndrome in 1994 (Table 1) [2]. Takase 
et al. [3] described a newer diagnostic criteria which includes: six ocular findings in the 
early stage, five clinical courses, and the virologic tests of intraocular fluids.
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2.1 The six ocular findings include
(1a) Presence of anterior chamber cells or mutton-fat keratic precipitates.
(1b) Presence of yellow-white lesion in the peripheral retina (granular or patchy 
in the early stage, then gradually merging.
(1c) Associated retinal arteritis.
(1d) Presence of hyperemic optic disc.
Figure 1. 
(a) Fundus photo of left eye showing media haze with vitritis, (b) herpes zoster lesions on the scalp, (c) 
peripheral fundus pictures showing deep yellowish white patches, in the peripheral retina and spreading 
concentrically with adjoining active vasculitis, and (d) resolution of the whitish lesion with valacyclovir 1 g 
TDS after 6 weeks.
Required clinical criteria Supporting clinical criteria
One or more foci of retinal necrosis with discrete borders, 
located in peripheral retina
Optic neuropathy/atrophy
Rapid progression of disease in the absence of therapy Scleritis
Circumferential spread of disease Pain
Evidence of occlusive vasculopathy and arteriolar 
involvement
A prominent inflammatory reaction in the vitreous and 
anterior chamber
Table 1. 
American uveitis society criteria for diagnosis of acute retinal necrosis.
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(1e) Presence of inflammatory vitreous opacities.
(1f) Associated elevated intraocular pressure (IOP).
2.2 The five clinical courses include
(2a) Rapid expansion of retinal lesion circumferentially.
(2b) Development of retinal breaks or retinal detachment.
(2c) Associated retinal vascular occlusion.
(2d) Associated optic atrophy.
(2e) Response to antiviral agents.
2.3 Virologic testing
It consists of the intraocular fluid analysis by using PCR or the Goldmann-
Witmer (GW) coefficient for HSV-1, HSV-2, or VZV. A “virus-confirmed ARN” was 
defined as the presence of ocular findings in stage 1a and 1b, the presence of any one 
of the five clinical courses, and a positive virologic test result. A “virus-unconfirmed 
ARN” was defined by them as the presence of four of six early stage ocular find-
ings including 1a and 1b, presence of any two of the five clinical courses, a negative 
virologic test result, or when virologic testing had not been performed [3].
Clinical appearance of retinitis is deep yellowish white patches, typically begin-
ning in the peripheral retina and spreading concentrically and towards the posterior 
pole (Figure 1c and d). An active vasculitis (Figure 1a) is present, with perivascular 
hemorrhages, sheathing, and terminal obliteration of arterioles by thrombi lasting 
about 4–6 weeks [4, 5].
Frequently the necrotic and normal retinal edge acts a site for developing fresh 
retinal breaks, with a 75% risk for developing rhegmatogenous retinal detachment 
(RRD) in untreated eyes [6]. Systemically these patients have a risk for developing 
meningoencephalitis and a neurologic symptoms should be borne in mid while 
treating such patients [7, 8].
3. Etiology
Considerable evidence points to multiple members of the herpesvirus family in 
the etiology of ARN syndrome with VZV (Figure 1b) [7] being the leading cause 
followed HSV [9] and rarely by CMV and EBV [10].
3.1 Histopathology
Studies of blind eyes enucleated early in the course of ARN have demonstrated 
retinal necrosis with eosinophilic intranuclear inclusions within cells of all layers of 
retina and retinal pigment epithelium. Immune complex deposition for VZV and 
HSV antigen can be noted in the retinal vessels [11].
The differential diagnosis that need to be rules out include CMV retinopathy, 
syphilitic retinitis, toxoplasmosis, large cell lymphoma, hemorrhagic vasculitis and 
Progressive outer retinal necrosis [10].
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ARN is a syndrome whose clinical diagnosis is established on the basis of the 
evolving signs and symptoms, which may be pathognomonic in many cases, but in 
atypical cases ancillary clinical history or laboratory tests help in supporting and 
identifying the diagnosis [1, 2]. The patient’s level of immunocompetence has to 
be determined, as this adds knowledge of the seropositivity to HIV and syphilis 
and may help to establish an appropriate and specific diagnosis. The most sensi-
tive and specific method for the detection of herpes viruses in vitreous specimens 
is the polymerase chain reaction (PCR) [3–7]. Genomic DNA of human herpes 
virus (HHV), toxoplasma, bacteria, and fungi can be measured in the aqueous 
humor and vitreous fluids using of two independent PCR assays either a qualitative 
multiplex PCR or a quantitative real-time PCR and secondly a broad-range real-
time PCR. The multiplex PCR can qualitatively measures the genomic DNA of eight 
different types of HHVs: (HSV) type 1 (HHV-1), HSV-2 (HHV-2), (VZV; HHV-3), 
Epstein-Barr virus (EBV; HHV-4), CMV (HHV-5), HHV-6, HHV-7, HHV-8, and 
toxoplasma [3]. PCR is now capable of detecting a single varicella zoster with a 
positivity of 86.4% and it was noted that aqueous sample yields a lesser chance for 
detection of virion in comparison to vitreous biopsy [12, 13].
Takase et al. [3] observed the overall rate of positive results of PCR for HSV-1, 
HSV-2, or VZV was 95% for ARN and 8% for control uveitis, a difference that 
was statistically significant [3]. In cases in which PCR is negative but a high clini-
cal suspicion, endoretinal biopsy and a central spinal fluid tap has been deemed 
more appropriate. Taking the biopsy from the transition zone between normal and 
necrotic retina during the acute phase of the disease greatly increases its diagnostic 
yield [12]. Another method for detection of intraocular viral infection can be 
achieved by measuring the viral antibody titers (FA) in serum and intraocular fluids 
and then calculating the quotient ratio (Q value or Goldmann-Witmer coefficient). 
If the Goldmann-Witmer coefficient of 1 or above is obtained, it is establishes proof 
of intraocular specific antibody production, hence intraocular infection should be 
suspected. However, the positivity of the Goldmann-Witmer coefficient can vary 
with time and from onset of ARN syndrome [3, 14].
4. Prognosis and treatment
Literature states that a generally poor prognosis in untreated eyes is expected in 
eyes with classic ARN syndrome and only 28% of affected eyes end up obtaining a 
final vision better than 20/200 as there are coexistent risks of RRD (75% of affected 
eyes), optic nerve dysfunction, or macular abnormality [6].
In the recent era of antiviral therapy and vitrectomy techniques have enabled 
in decreasing the level of vision loss associated with ARN to less than one-third of 
cases in recent years [15]. However, the use of prophylactic laser photocoagulation 
has become more controversial than it was in the past [16]. The comparison of 
lasered and non-lasered eyes as analyzed by Roy et al. [17], concluded that many 
eyes with severe ARN with the presence of vitreous inflammatory opacifica-
tion usually preclude the application of laser, whereas eyes with mild ARN with 
relatively clear media allows the application of laser. They noted that prophylactic 
laser retinopexy failed to prevent secondary RD and found no protective role in 
preventing RRD’s even after laser retinopexy, because the involved retinal area 
continues to extend posteriorly beyond the demarcation of the laser burns. It 
was concluded that eyes in which laser treatment was possible, obviously had 
less retinitis and hence vitritis, which ultimately gave them a better final visual 
prognosis [17].
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5. Treatment
(1g)Acyclovir is given intravenously for 5–10 days of 1500 mg/m2/day in three 
divided does with normal renal function tests. This is followed by oral acyclovir 
dose 800 mg (orally) 5 times daily for 6 weeks. The side-effects which close 
monitoring include decreased renal function, gastrointestinal irritation, phlebitis, 
central nervous system dysfunction, and hypersensitivity reactions. The most 
potent antiviral action is against VZV, HSV types 1 and 2, EBV, but a low activity has 
been noted in various studies against CMV [17].
(1h) Valacyclovir [l-valyl ester of acyclovir], has better bioavailability and is 
used in the doses of 1 g three times a day for 6–8 weeks. Treatment algorithms as 
cited in literature used oral valacyclovir 1 g 3 times daily, oral famciclovir 500 mg 
3 times daily, or valganciclovir 450–900 mg 2 times daily until complete resolution of 
retinitis was observed [17, 18]. Renal function need to be monitored for all antivirals 
are administered on a long-term basis, especially in extremes of age.
(1i) Adjunctive role for intravitreal antiviral medication in the treatment of ARN 
syndrome has been explored in early remission of the retinitis. The original dose 
of ganciclovir used was 200 or 400 mcg in 0.1 ml, but nowadays the dose is 2 mg 
in 0.05–0.1 ml. The injections are given on a weekly basis. Intravitreal foscarnet in 
humans at a dose of 2.4 mg in 0.1 ml has also been reported to be safe and effective in 
treating retinitis caused by cytomegalovirus followed with a maintenance dose once 
a week, with a close monitoring for optic and retinal toxicity. Intravitreal therapy 
forms a part of palliation therapy for patients who are unable to tolerate or refuse 
systemic treatment, or as an adjunct in severe disease. However, studies have demon-
strated efficacy as good as or better than intravenous treatment [18, 19].
(1j) Systemic corticosteroids also may limit intraocular inflammation and the 
vitreous reaction, but are generally begun only after 24–48 h of intravenous acyclo-
vir/oral valacyclovir [20].
(1k) The combination of systemic and intravitreal therapy has been reported as 
new a treatment paradigm for patients with ARN. Flaxel et al. conducted a com-
parative case series and analyzed in 24 patients with ARN treated over a 20-year 
period. They had 12 patients in the study who received combination systemic and 
intravitreal antiviral therapy while 12 patients received only systemic therapy alone. 
Patients receiving combination therapy showed a higher incidence of two-line-or-
greater visual acuity and decreased incidence of RD and severe visual acuity loss 
to 20/200 or poorer when compared to patients who received systemic antiviral 
alone and similar results were obtained by Wong et al. and Megphara et al. They 
concluded that patients that with moderate disease (i.e., 25–50% retina involved) 
usually showed better results. However, Tibbetts et al. found no statistically sig-
nificant difference in the visual acuity and prevalence of retinal detachment with 
combination therapy [21].
In recent years the use of adjunctive intravitreal antivirals has increased as it 
enables a high concentration of antiviral agent to reach where it is needed most. 
Intravitreal foscarnet was used in 46.7% of patients by TF Cochrane et al. in their 
study and linked its use with a no specific reduction in the rate of retinal detach-
ment versus eyes treated without intravitreal therapy. No specific guidelines have 
been outlined with the use and number of injections required for controlling the 
viral retinitis [13, 17, 18].
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Kawaguchi et al. described an algorithm where they used combination of 
antiviral, anti-inflammatory and antithrombotic treatment depending on virus 
isolated. They suggested that higher doses of systemic acyclovir (10 vs. 15 mg/kg), 
oral prednisolone (30 vs. 40–60 mg/d) and aspirin (100 vs. 200–300 mg/d) should 
be given to those with VZV ARN [13]. Till date no specific trial has validated the 
efficacy of virus specific.
Treatment and all current treatment options available for ARN are based on 
anecdotal evidence.
Before the antiviral management the reported incidence of second eye involve-
ment was 36% in ARN patients, usually within 6 weeks. However with better 
management, most of the recent studies conclude a fellow-eye involvement rate 
of around 3% with appropriate antiviral treatment [6, 18]. The duration for which 
the systemic treatment should be continued to prevent fellow-eye involvement is 
not well established in literature. The risk is believed to be decrease if therapy is 
continued for 6–12 weeks. The incidence of bilateral ARN reported in literature has 
been as late as 34 years after the first eye became affected [18]. The syndrome of 
ARN is a potentially visually devastating disorder with multifactorial pathogenesis. 
Its successful management depends on further advances in antiviral chemotherapy, 
control of the ischemic vasculopathy, and prevention of proliferative vitreoreti-
nopathy [1, 5, 22].
To conclude ARN is a rare but potentially visually devastating condition 
and both qualitative and quantitative real-time PCR testing may be used both 
to ascertain the etiology of ARN and to assess the response to therapy. During 
the last few years the first-line of therapy has been the use of oral prodrugs 
valacyclovir, famciclovir and valganciclovir which has gained popularity because 
the patients do not have to be hospitalized with oral therapy in contrast to intra-
venous therapy and thus preventing the devastating complications. It is still a 
matter of debate from most of the studies whether and where all prophylactic 
laser is deemed beneficial in preventing RRD. Intravitreal antiviral therapy acts 
in supportive role in combination with the oral antiviral therapy for better visual 
outcomes.
6. Cytomegalovirus retinitis
CMV is ubiquitous entity and its seroprevalence rises from nearly 60% in patients 
6 years or older to greater than 90% in individuals more than 80 year of age [23].
In immunocompetent individuals the initial infection with CMV causes 
minimal symptoms, although an associated mononucleosis-like syndrome can be 
a presentation. Cell-mediated immunity helps to control the virus and prevents 
specific organ disease in all, but may affect a few patients [24]. However, in 
the presence of advanced immunosuppression, such as AIDS, history of organ 
transplantation with iatrogenic immunosuppression, autoimmune disease, or 
malignancy are a higher risk of developing specific end-organ CMV disease (e.g., 
encephalitis, esophagitis, colitis, and retinitis), thus increasing the risk of morbid-
ity and mortality [23–25].
7. Ophthalmoscopic findings
The diagnosis of CMV is based on clinical appearance and correlating it with 
a supportive history of an immunocompromised state. The retinal lesions appear 
peripherally in a perivascular distribution as a creamy white infiltrate and associated 
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granular borders surrounded with smaller satellite lesions (Figure 2a and b). There 
is a space of “clear” retina separating in between the granular foci. Progression of 
active retinitis causes scarring (Figure 2c), suggesting the virus involvement from 
the beginning. The active border progresses posteriorly, at a rate of 250–350 μm/
week, causing scarring and adjoining necrosis of retina (Figure 2f) with mottled 
pigmentation of the RPE. The term “pizza pie” appearance is associated with CMV if 
the retinitis lesions are presenting more posteriorly thus involving the retinal vessels 
and causing retinal hemorrhages (Figure 2a) [25, 26].
A second pattern of CMV retinitis has as describes includes a “granular” or 
“brushfire border.” The focal granular infiltrates enlarge slowly and advancement 
is associated with destruction of the retina and leaving a atrophic retinal pigment 
epithelium behind. Hemorrhages and vitreous cells are less prominent seen. This 
is attributed to be direct cell-to cell transfer of infected virions in this pattern of 
infection. The brushfire border is commonly seen in the anterior to the equator 
[24–27].
The clinical appearance of newly diagnosed CMV retinitis has not altered 
appreciably from the pre-highly antiretroviral therapy (HAART) era to the HAART 
era [26]. A delay in diagnosis increases the risk of vision loss either due to fulminant 
retinitis (foveal or optic nerve involvement), or it may induce immune recovery 
uveitis (IRU) and its associated sequelae increase with the severity of CMV retinitis 
in elderly, healthy patients with CMV retinitis. The delayed diagnosis causes retinal 
arteriolar occlusions, with poor visual outcomes [27].
Histopathologically there is presence of extensive areas of necrosis with diffuse 
or full thickness retinal involvement. In the areas of necrosis intracytoplasmic as 
well intranuclear inclusions resembling ‘Owl eyes’ can be noted. The majority of the 
enlarged cells are in the range of 20–30 μm with intranuclear basophilic inclusion 
and numerous eosinophilic intracytoplasmic inclusions [28].
Figure 2. 
(a) Fundus picture of right eye of a female patient presented with diminution of vision after renal transplant, 
with posterior active vasculitis with presence of hemorrhages, (b) (superior retina just above the arcade) 
a mid-peripheral perivascular vitritis with a creamy white infiltrate, with a more granular border, (c) the 
area of resolution of the whitish lesion after treatment with 450 mg B.D of valganciclovir after 3 months, (d) 
recurrence at the edge of the lesion 2 months post tapering dose of valganciclovir, (e) resolution of the recurrence 
at the edge with initiation of 450 mg B.D of valganciclovir, and (f) an wide field image at last follow where 
patient underwent intravitreal ganciclovir injection 2 mg/0.5 ml with oral valganciclovir, showing resolution of 
the retinitis with peripheral scarring and gliosis.
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8. Clinical findings of CMV retinitis in non-HIV-positive patients
In elderly immune-competent patients (other than the natural waning of immu-
nity and increased prevalence of typical comorbidities that come with age), CMV 
retinitis tends to have an increased association with retinal arteriolar occlusions, 
even with minimal retinitis. In patients with limited immune dysfunction (due to 
old age, diabetes, or noncytotoxic immunosuppression), CMV retinitis can present 
with typical peripheral, granular, and slowly progressive retinitis and an atypical 
panretinal occlusive vasculitis, mimicking ARN [29].
8.1 Biochemical testing
In cases of diagnostic dilemma, especially in the absence of an identifiable 
source of host immunosuppression, polymerase chain reaction (PCR) of aqueous or 
vitreous samples can amplify CMV DNA and secure a diagnosis. Recently, a loop-
mediated isothermal amplification (LAMP) assay has demonstrated 100% concor-
dance with PCR in detecting CMV DNA in vitreous samples of patients suspected 
or diagnosed as CMV retinitis at a fraction of the cost, potentially increasing the 
diagnostic capabilities of clinicians in [30, 31].
8.2 Screening
All HIV individuals with CD4+ T cell counts <50 cells/μL, need a screening by a 
uveitis or retinal specialist using dilated fundus exams every 3 months [27].
In patients undergoing allogenic hematopoietic stem cell transplanta-
tion (HSCT) after conditioning with an alemtuzumab (Campath, Genzyme, 
Cambridge, MA)-based regimen, the frequency of CMV retinitis can approach 24% 
and similarly, post-HSCT patients with a significant CMV viral load (peak CMV 
DNA level >7.64 × 104 copies/mL) are at increased risk of developing CMV retinitis 
and require periodic screening for ruling out retinitis [32].
8.3 Management
Because no currently available agent is virucidal, the goal of therapy is to arrest 
viral replication/assembly until the host’s immune system has recovered sufficiently 
to assume this function. Factors to be considered in selecting the mode of therapy 
include the patient’s potential for immunologic improvement, the location and 
severity of CMV retinitis, and the risks, costs, and convenience associated with 
various therapies [32].
In the setting of HIV/AIDS, initiation of HAART is the most critical step in plan-
ning for long-term suppression of CMV retinitis. In the event that immune system 
recovery is unexpected (i.e., transplant recipients requiring lifelong immunosup-
pression), the physician should provide indefinite virostatic treatment [32].
The treatment for CMV retinitis includes three intravenous drugs: oral or 
intravenous ganciclovir, intravenous foscarnet and intravenous cidofovir. The role 
of systemic therapy is by starting at a higher induction dose for 2–3 weeks, followed 
by lower maintenance doses as it helps in preventing relapses of the retinitis. 
The purposed mechanism of action is specific selective inhibition of viral DNA 
 polymerase [32].
The treatment of choice includes intravenous ganciclovir in in two divided doses 
for 2 weeks of initial induction therapy (5–7 mg/kg/day), followed by a once-daily 
maintenance dose. It is continued until the lesions begin to resolve and the patient’s 
immune status shows improvement. Oral valganciclovir 900 mg twice daily as 
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induction therapy followed by 900 mg once daily as maintenance dose as it serves 
an additional advantage of being a non-parenteral mode of treatment and avoiding 
complications relating to indwelling catheters, especially in immunocompromised 
patients. Foscarnet is administered as 90 mg/kg, twice daily for 14–21 days, as 
induction therapy, followed by once-daily administration as maintenance therapy. 
It is the preferred treatment of choice in Ganciclovir resistant cases [19, 32–34].
Recently the use of oral valganciclovir (Valcyte, Roche), an l-valyl ester prodrug 
of ganciclovir, is preferred as it obviates the risks due to intravenous therapy, but the 
cost of therapy and its related myelosuppression remain an issue. The bioavailability 
of 60% is obtained by the drug, which is comparable to intravenous ganciclovir and 
far greater than with oral ganciclovir (5%). Several newer antiviral agents are in 
various stages of preclinical experiments to phase 2 clinical trials include: Cidofovir, 
Maribavir (GlaxoSmithKline, Philadelphia, PA), BAY 38-4766 (Bayer, Pittsburgh, 
PA), and AIC246 (AiCuris, Wuppertal, Germany), inhibit viral activity through 
pathways other than the inhibition of viral DNA polymerase [33].
8.4 Intravitreal therapy
The preferred intravitreal injections consist of either ganciclovir or foscar-
net, with or without systemic medication, to control sight-threatening retinitis. 
Induction dosing with intravitreal medications requires injections two to three 
times weekly, while once weekly generally is sufficient for maintenance.
1. Ganciclovir: the original dose used was 200 or 400 mcg in 0.1 ml, but almost 
all injections given today are 2 mg in 0.05–0.1 ml. The injections are given 
on a weekly basis. It is also available as an intraocular ganciclovir implant 
(Vitrasert, Bausch + Lomb, Rochester, NY) and demonstrated superiority over 
intravenous ganciclovir in terms of median time to the progression of retinitis 
(221 days for the 1 μg/h implant vs. 71 days for intravenous ganciclovir). 
Complication rates associated with the ganciclovir implant, most commonly 
for cataract, vitreous hemorrhage, and retinal detachment [20].
2. Foscarnet: it is used in the dose of 2.4 mg per 0.1 ml. It is used as twice weekly 
injections for induction period and once a week for maintenance therapy. They 
may be more effective in cases of resistant CMV disease. Combinations of 
high-dose intravitreal ganciclovir (3.0 mg twice a week) and foscarnet (2.4 mg 
twice a week) may be effective in patients who fail to respond or are intolerant 
to conventional therapy for ARN and HSV-1 retinitis. The most commonly 
reported complications include cataract, vitreous hemorrhage, and retinal 
detachment [34]
3. Cidofovir: the long half-life and potent anti-CMV activity of Cidofovir make it 
an attractive candidate for intravitreal injection. Studies in rabbits suggested 
that 100 mcg was a safe dose. Increased proteinuria and elevations in serum 
creatinine are the major dose limiting toxicities [19, 34, 35].
4. Fomivirsen: Vitravene, (Isis Pharmaceuticals Inc., Carlsbad, CA, USA) has also 
been studied for intravitreal use in patients with CMV retinitis, especially in 
situations where conventional therapy such as systemic and intravitreal gan-
ciclovir, foscarnet, or cidofovir have failed or are contraindicated. Induction 
doses of fomivirsen are administered intravitreally at a dose of 330 mcg once 
every 2 weeks for 2 doses followed by maintenance therapy at same dose every 
4 weeks [19, 34].
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9. Treatment options in resistance
The treatment of CMV retinitis in the setting of drug resistance remains a 
particular challenge as newer antivirals take time to reach the level of commercial 
availability. Oral leflunomide (Arava, Sanofi-Aventis, Bridgewater, NJ), an immu-
nosuppressive agent with anti-CMV activity, has demonstrated efficacy in trans-
plant patients with systemic CMV infection and also in multi-drug-resistant CMV 
retinitis [36].
10. Conclusion
The evident benefits of HAART have helped in decreasing incidence and 
severity in immune compromised patients but still CMV retinitis remains the most 
common ocular opportunistic infection. Patients with a CD4+ T cell count <50 are 
at increased risk of CMV retinitis, and frequent screening of these patients is the 
need of the hour to detect the disease before it becomes sight-threatening [36].
10.1 Progressive outer retinal necrosis
Progressive outer retinal necrosis (PORN, also known as VZV retinitis or rapidly 
progressive herpetic retinal necrosis) was described and cited most by Engstrom 
and colleagues in 1994. They established about its devastating nature, in which 
two-thirds of eyes progressed to no light perception (NLP) within 4 weeks of onset. 
They concluded that most patients with this syndrome have had low CD4 cell 
counts (i.e., below 50/ml). It is mostly found in immunocompromised patients and 
diagnosis is based on the presence of:
1. Multifocal lesions with deep retinal opacification without granular borders 
with some areas of confluent opacification.
2. Peripheral retina location, with or without macular involvement.
3. Rapid progression.
4. Absence of vascular inflammation.
5. Minimal or no intraocular inflammation.
6. Perivascular clearing of the retinal opacification (hallmark of PORN 
syndrome).
7. Immunocompromised or patients with immunosuppression [37, 38].
Therapy of PORN often requires immediate high-dose anti-zoster or -HSV 
therapy. The earliest reports of treatment of PORN with single intravenous anti-
virals, primarily acyclovir, showed poor visual results. Recently the studies have 
shown an improvement in the visual outcomes with the combination use of intrave-
nous and intravitreal antiviral treatment [38].
Scott et al. have reported that final vision of 20/80 or better in 5 of 11 eyes 
(45%) and only two of 11 eyes (18%) progressing to NLP vision. This was achieved 
utilizing a regimen of intravitreal ganciclovir and foscarnet plus IV foscarnet and 
IV ganciclovir or oral valganciclovir [39].
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Gore et al. have the largest published series of patients with PORN treated with 
intravitreal ganciclovir antiviral therapy, found an improvement in final vision, 
with only 9 (13%) eyes losing perception of light. They observed that the retinas 
in patients receiving HAART when first evaluated were significantly less likely to 
detach and had a bimodal distribution to retinal detachment, the vast majority of 
retinas detaching within the first few weeks (i.e., during the active necrotic phase) 
and a few detaching many months later (i.e., during the inactive phase). The early 
group can be explained by full-thickness necrosis, leading to holes though both the 
inner and outer retina, as a prelude to RRD. For delayed RRD’s they proposed that 
some retina’s are associated with one or more sieve-like holes that can occasionally 
self-seal with the ensuing scarring process, allowing a functioning retinal pigment 
epithelium to pump the detachment flat [39].
Despite some patients being able to retain workable good vision, the overall 
functional outcomes remain alarming as a result of the catastrophic loss of vision 
PORN can lead to. The most encouraging results are achieved with improved visual 
outcomes when associated with early response to intravitreal ganciclovir injections. 
The best outcomes are limited to be seen in patients who begin intravitreal (and 
systemic) therapy within a few days of symptom onset, before macular involvement 
is apparent [39].
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